Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GlaxoSmithKline ( (GSK) ) has provided an announcement.
GSK plc said on 26 February 2026 that China’s National Medical Products Administration has accepted its new drug application for linerixibat for priority review to treat cholestatic pruritus in patients with primary biliary cholangitis, a rare autoimmune liver disease. The oral IBAT inhibitor previously showed rapid, significant and sustained itch and sleep-related improvements versus placebo in the phase III GLISTEN trial, with a safety profile consistent with prior studies.
The move underscores GSK’s push into hepatology and could address a major unmet need in China, where around 280,000 people are affected by PBC and up to 89% experience cholestatic pruritus with few effective options. Linerixibat has orphan drug status in the US, EU and Japan, while parallel marketing reviews are under way in the US, EU, UK and Canada, positioning the asset as a potential first-in-class global therapy if approvals follow.
The most recent analyst rating on (GSK) stock is a Hold with a $70.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is supported primarily by resilient fundamentals (strong profitability and positive cash generation) and a constructive earnings outlook with higher dividend guidance and continued specialty/HIV momentum. These positives are tempered by leverage and recent revenue/FCF volatility, while technically the stock is in a strong uptrend but looks overbought, raising near-term pullback risk.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company focused on uniting science, technology and talent to develop medicines that get ahead of disease. The group is extending its inflammation expertise into hepatology, advancing a pipeline targeting chronic and fibro-inflammatory liver diseases such as chronic hepatitis B and steatotic liver disease, including MASH and alcohol-associated liver disease.
Average Trading Volume: 4,919,155
Technical Sentiment Signal: Buy
Current Market Cap: $120.5B
See more data about GSK stock on TipRanks’ Stock Analysis page.